244 related articles for article (PubMed ID: 25707631)
1. A framework for a personalized surgical approach to ovarian cancer.
Nick AM; Coleman RL; Ramirez PT; Sood AK
Nat Rev Clin Oncol; 2015 Apr; 12(4):239-45. PubMed ID: 25707631
[TBL] [Abstract][Full Text] [Related]
2. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
[TBL] [Abstract][Full Text] [Related]
3. Role of aggressive surgical cytoreduction in advanced ovarian cancer.
Chang SJ; Bristow RE; Chi DS; Cliby WA
J Gynecol Oncol; 2015 Oct; 26(4):336-42. PubMed ID: 26197773
[TBL] [Abstract][Full Text] [Related]
4. [Advanced ovarian cancer: primary debulking (PDS) or neoadjuvant chemotherapy (NACT) - still a debate].
Segev Y; Gemer O; Auslender R; Lavie O
Harefuah; 2014 Sep; 153(9):527-31, 558. PubMed ID: 25417489
[TBL] [Abstract][Full Text] [Related]
5. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.
Chang SJ; Hodeib M; Chang J; Bristow RE
Gynecol Oncol; 2013 Sep; 130(3):493-8. PubMed ID: 23747291
[TBL] [Abstract][Full Text] [Related]
6. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining 'optimal' residual disease.
Chang SJ; Bristow RE
Gynecol Oncol; 2012 May; 125(2):483-92. PubMed ID: 22366151
[TBL] [Abstract][Full Text] [Related]
7. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.
Fleming ND; Nick AM; Coleman RL; Westin SN; Ramirez PT; Soliman PT; Fellman B; Meyer LA; Schmeler KM; Lu KH; Sood AK
Obstet Gynecol; 2018 Sep; 132(3):545-554. PubMed ID: 30095787
[TBL] [Abstract][Full Text] [Related]
8. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
9. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
10. Surgical cytoreduction during second-look laparotomy in patients with advanced ovarian cancer.
Gadducci A; Iacconi P; Fanucchi A; Cosio S; Teti G; Genazzani AR
Anticancer Res; 2000; 20(3B):1959-64. PubMed ID: 10928134
[TBL] [Abstract][Full Text] [Related]
11. Minimally invasive interval cytoreductive surgery in ovarian cancer: systematic review and meta-analysis.
Cardenas-Goicoechea J; Wang Y; McGorray S; Saleem MD; Carbajal Mamani SL; Pomputius AF; Markham MJ; Castagno JC
J Robot Surg; 2019 Feb; 13(1):23-33. PubMed ID: 29992404
[TBL] [Abstract][Full Text] [Related]
12. Update on the role of surgery in the management of advanced epithelial ovarian cancer.
Straubhar A; Chi DS; Long Roche K
Clin Adv Hematol Oncol; 2020 Nov; 18(11):723-731. PubMed ID: 33406064
[TBL] [Abstract][Full Text] [Related]
13. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
14. Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
Seward SM; Winer I
Cancer Metastasis Rev; 2015 Mar; 34(1):5-10. PubMed ID: 25597035
[TBL] [Abstract][Full Text] [Related]
15. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
16. Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery.
Lakhman Y; Akin O; Sohn MJ; Zheng J; Moskowitz CS; Iyer RB; Barakat RR; Sabbatini PJ; Chi DS; Hricak H
AJR Am J Roentgenol; 2012 Jun; 198(6):1453-9. PubMed ID: 22623562
[TBL] [Abstract][Full Text] [Related]
17. A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study.
Feng Z; Wen H; Jiang Z; Liu S; Ju X; Chen X; Xia L; Xu J; Bi R; Wu X
J Gynecol Oncol; 2018 Sep; 29(5):e65. PubMed ID: 30022629
[TBL] [Abstract][Full Text] [Related]
18. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
Chi DS; Eisenhauer EL; Lang J; Huh J; Haddad L; Abu-Rustum NR; Sonoda Y; Levine DA; Hensley M; Barakat RR
Gynecol Oncol; 2006 Nov; 103(2):559-64. PubMed ID: 16714056
[TBL] [Abstract][Full Text] [Related]
19. [Neoadjuvant chemotherapy and ovarian cancer].
Ray-Coquard I; Saba C; Bachelot T; Méeus P; Mignotte H; Blondet R; Treilleux I; Peix M; Guastalla JP
Bull Cancer; 2006 Jul; 93(7):669-76. PubMed ID: 16873075
[TBL] [Abstract][Full Text] [Related]
20. An overview of the current debate between using minimally invasive surgery versus laparotomy for interval cytoreductive surgery in epithelial ovarian cancer.
Finch L; Chi DS
J Gynecol Oncol; 2023 Sep; 34(5):e84. PubMed ID: 37545363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
